This roundtable series examines systemic therapies and other options approvedin those with steroid-refractorychronic graft-vs-host disease, as discussed by key opinion leaders and participants at virtual live events.
Biology Informs Treatment Options for Steroid-Refractory Chronic GVHD
February 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.
Different Approaches Available for Identifying and Managing Chronic GVHD
January 22nd 2024In the first article of a 2-part series, Lori Muffly, MD, MS, discusses with a panel of physicians what their approach is to identifying patients with severe chronic graft-versus-host-disease and how they treat them in conjunction with the transplant team.
Acknowledging Different Considerations for Ruxolitinib in Severe GVHD
February 26th 2024In the second article of a 2-part series, Lori Muffly, MD, MS, leads a discussion on how treatment considerations change when a patient has severe graft-vs-host disease or if the involvement is in the lung and where ruxolitinib fits into treatment.